GFAP and Alzheimer disease: Blood GFAP performance is an exception showing good performance,20 whereas other inflammation‐related biomarkers with clear changes in the CSF of AD patients, such as sTREM2 and YKL‐40, have shown mixed results in plasma.27, 28, 29, 30